Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Subscribe To Our Newsletter & Stay Updated
